ResMed Inc.
(NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
The move reflects ResMed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. • ResMed stock is showing downward pressure.
What should traders watch with RMD?
The divestiture also strengthens ResMed’s ability to reallocate capital and resources toward innovation, operational scale, and long-term value creation across its connected, home-based care ecosystem.
